10-K · March 4, 2026
OrthoPediatrics reports record 2025 revenue of $236.3 million (up 15% vs. 2024) while continuing to operate at a loss but showing margin and cash-flow improvement late in the year. The company emphasizes its exclusive…
Earnings analysis · 10-Q
KIDS earnings analysis
Filed May 1, 2026 · Our reading of the company's report
The latest report
OrthoPediatrics reported revenue of $59.4 million for Q1 2026, an increase of 13% from $52.4 million year-over-year. The EPS loss was $0.42, slightly better than the expected loss of $0.43, reflecting positive sales…
Read full summary
OrthoPediatrics reported revenue of $59.4 million for Q1 2026, an increase of 13% from $52.4 million year-over-year. The EPS loss was $0.42, slightly better than the expected loss of $0.43, reflecting positive sales trends in key product segments. Management raised full-year revenue guidance to between $263 million and $267 million, indicating optimism despite ongoing challenges with operating losses.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.42
- Gross margin
- 73%
What stood out
-
Revenue Growth of 13%
Q1 2026 revenue was $59.4M, up from $52.4M in Q1 2025, reflecting strong market demand.
-
Improved EPS Performance
Reported diluted EPS was -$0.42, beating estimates of -$0.43 by 2.3%.
-
Positive Gross Margin Stability
Gross margin remained stable at 73%, reflecting effective cost management despite increased sales.
-
Strong U.S. Sales Increase
U.S. sales rose to $45.3M in Q1 2026 from $40.9M in Q1 2025, a growth of 10.8%.
-
International Sales Growth
International revenue also grew from $11.5M to $14.1M, a 22% increase year-over-year.
-
Raised Full-Year Revenue Guidance
Management increased full-year revenue guidance to between $263M and $267M, up from $262M-$266M.
What to watch
-
Negative Operating Cash Flow
Operating cash flow of -$3.3M in Q1 2026, showing persistent cash usage for operations.
-
Accumulated Deficit Continues
Accumulated deficit reached $285.9M, raising concerns about long-term sustainability.
-
High Operating Expenses Impact
Sales and marketing expenses increased by 11%, putting pressure on profitability despite revenue gains.
Management's outlook
Revenue guidance for 2026 raised to $263M-$267M, reflecting optimism in market growth.
Earlier filings 4
10-Q · August 6, 2025
OrthoPediatrics reported Q2 net revenue of $61.082 million, a 16% increase vs. $52.802 million in Q2 2024, driven by Trauma & Deformity and Scoliosis. Gross margin compressed to 72% from 77% a year ago while GAAP net…
10-Q · November 7, 2024
OrthoPediatrics reported Q3 net revenue of $54.6M, up $14.6M or 37% year-over-year, driven by the Boston O&P acquisition and strength in Trauma & Deformity and Scoliosis. Gross margin compressed to 73% from 77% a year…
10-K · March 8, 2024
OrthoPediatrics Corp. reported total revenue of $148.7 million in 2023, reflecting a significant increase from $122.3 million in 2022, resulting in a compound annual growth rate of 25.0% since 2011. The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.